Replies to post #88545 on Anavex Life Sciences Corp (AVXL)

[Reyeton]

An arthritis doctor prescribed a drug approved for treating malaria to treat my wife's arthritis. I don't remember the side effects of that drug, but were severe enough to say, No Thank You. 2-73 has a clean safety profile so I cannot see much resistance to prescribing it off-label for CNS diseases.

[sokol]

Despite what some have said on this board, FDA orphan approval of AVXL 2-73 for Rhetts is a big deal. It will mean 7 years FDA New Chemical Entity exclusivity, and you can bet that doctors will write off label prescriptions for conditions other than for Rhetts. The latter is especially true if the clinical trials for Alzheimer's, Parkinson's, etc., are demonstrating positive results. Plus, Anavex may in the interim file for and obtain longer patent protection. You can bet that families will be requesting prescriptions from doctors for the dreaded diseases that AVXL 2-73 may benefit. Who wouldn't request an off label prescription for AVXL 2-73 for Alzheimer's when no other drug on the market is actually working? And, doctors will write those off label prescriptions as I know they have written off label prescriptions for other drugs in the past.